Giuseppe Curigliano, Member of the Editorial Board for OncoDaily and President Elect of ESMO, posted on LinkedIn, about recent paper he and colleagues co-authored:
“Just published in Annals of Oncology: “ESMO Precision Oncology Working Group Recommendations on the Structure and Quality Indicators for Molecular Tumour Boards in Clinical Practice”.
This paper marks a significant step forward in ESMO’s commitment to expanding access to precision oncology across Europe and beyond.
- Why it matters: Molecular Tumour Boards (MTBs) are critical to interpreting complex genomic data and guiding personalized treatment decisions. But without clear structure and quality standards, their potential is underused and unevenly distributed.
- What’s new: ESMO proposes a comprehensive framework for the optimal setup, functioning, and evaluation of MTBs—aimed at ensuring high-quality, equitable molecular diagnostics and therapy matching for all cancer patients, not just a privileged few.
- The goal: democratize access to precision medicine by promoting standardized, multidisciplinary, and inclusive MTB models.
ESMO continues to lead the way in making precision oncology a reality for every patient, everywhere.”
Authors: C.B. Westphalen, L. Boscolo Bielo, P. Aftimos, H. Beltran, M. Benary, D. Chakravarty, M. Collienne, R. Dienstmann, A. El Helali, J. Gainor, P. Horak, C. Le Tourneau, C. Marchiò, C. Massard, F. Meric-Bernstam, C. Pauli, G. Pruneri, F. Roitberg, H.E.G. Russnes, D.B. Solit, G. Curigliano
Read Further: Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research.